Fewer isolates cultured from heavily pre-treated HIV patients were found to be resistant to Agenerase, according to in vitro data presented at ICAAC. Twenty-four percent of isolates demonstrated eight-fold resistance to amprenavir vs. 43% resistance to indinavir, 63% resistance to Abbott's Norvir (ritonavir), 61% resistance to Roche's Viracept (nelfinavir) and 53% resistance to Roche's Invirase/Fortovase (saquinavir)
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth